Vanda Pharmaceuticals (VNDA) sNDA for Fanapt Approved by U.S. FDA for Schizophrenia

Go back to Vanda Pharmaceuticals (VNDA) sNDA for Fanapt Approved by U.S. FDA for Schizophrenia

Brean Capital Positive on Vanda (VNDA) Amid FDA Approval

May 27, 2016 10:36 AM EDT

Brean Capital analyst, Difei Yang, noted that Vanda Pharmaceuticals (NASDAQ: VNDA) Fanapt sNDA on Schizophrenia Maintenance therapy was approved on May 26. The analyst expects a positive market reaction to the news and a possible market exclusivity decision by as early as June 17.... More